B:SM will break its investment record this year with 62 million euros
War in Ukraine: when kyiv attacks Russia with inflatable balloons loaded with explosives
United States: divided on the question of presidential immunity, the Supreme Court offers respite to Trump
Maurizio Molinari: “the Scurati affair, a European injury”
First three cases of “native” cholera confirmed in Mayotte
Meningitis: compulsory vaccination for babies will be extended in 2025
Spain is the country in the European Union with the most overqualified workers for their jobs
Parvovirus alert, the “fifth disease” of children which has already caused the death of five babies in 2024
Inflation rebounds in March in the United States, a few days before the Fed meeting
Video games: Blizzard cancels Blizzcon 2024, its annual high mass
Falling wings of the Moulin Rouge: who will pay for the repairs?
“You don’t sell a company like that”: Roland Lescure “annoyed” by the prospect of a sale of Biogaran
Exhibition: in Deauville, Zao Wou-Ki, beauty in all things
Dak’art, the most important biennial of African art, postponed due to lack of funding
In Deadpool and Wolverine, Ryan and Hugh Jackman explore the depths of the Marvel multiverse
Tom Cruise returns to Paris for the filming of Mission Impossible 8
Skoda Kodiaq 2024: a 'beast' plug-in hybrid SUV
Tesla launches a new Model Y with 600 km of autonomy at a "more accessible price"
The 10 best-selling cars in March 2024 in Spain: sales fall due to Easter
A private jet company buys more than 100 flying cars
This is how housing prices have changed in Spain in the last decade
The home mortgage firm drops 10% in January and interest soars to 3.46%
The jewel of the Rocío de Nagüeles urbanization: a dream villa in Marbella
Rental prices grow by 7.3% in February: where does it go up and where does it go down?
Even on a mission for NATO, the Charles-de-Gaulle remains under French control, Lecornu responds to Mélenchon
“Deadly Europe”, “economic decline”, immigration… What to remember from Emmanuel Macron’s speech at the Sorbonne
Sale of Biogaran: The Republicans write to Emmanuel Macron
Europeans: “All those who claim that we don’t need Europe are liars”, criticizes Bayrou
These French cities that will boycott the World Cup in Qatar
Euroleague: at the end of the suspense, Monaco equalizes against Fenerbahçe
Women's Six Nations: Where to see and five things to know about France-England
Liverpool: it is confirmed, Slot will succeed Klopp on the Reds bench
Ligue 1: Montpellier and Nantes back to back, two reds in stoppage time
The US company Moderna wants to apply for approval for an RSV vaccine for adults over 60 years of age in the first half of the year. The company said the vaccine, dubbed "mRNA-1345," has shown "promising results" in the phase 3 trial required for approval. Respiratory syncytial virus (RSV) causes respiratory disease.
The Robert Koch Institute counts among the risk patients, for example, premature babies and children with previous lung diseases as well as people with immunodeficiency or suppressed immune systems.
"We found that use of the vaccine reduced the risk of confirmed severe RSV disease by nearly 84 percent," said Paul Burton, Moderna's chief medical officer. The effectiveness of the vaccine against RSV-related diseases of the lower respiratory tract with two or more symptoms was examined. The safety profile was also very good. According to the company, around 37,000 people aged 60 and over from 22 countries took part in the study.
The so-called messenger RNA (messenger ribonucleic acid, mRNA) became known to a broad public through its use in the corona vaccines. The mRNA in vaccines delivers part of the genetic information of the virus to human cells. With this information, they produce a protein of the pathogen against which the body then develops defense reactions. In later contact with the pathogen, the immune system recognizes the protein and can fight the virus faster and more specifically.
"In this vaccine, we encapsulate this messenger RNA in the same lipid that we use for the Covid vaccine, which is used in hundreds of millions of people around the world," Burton said.
The vaccine developed is initially intended for people aged 60 and over. However, RSV can also be particularly dangerous for infants and young children. Moderna is also researching this, Burton said. “We have five other ongoing programs for young children, pregnant mothers and a number of other populations. We will also publish this data in the coming months.”
RSV had placed a heavy burden on children's hospitals in Germany and other countries this season. The combination of many influenza, corona and RSV cases also posed challenges for the health system. The goal is to combine different vaccines against respiratory viruses, such as corona and RSV, said Burton. However, such studies are more difficult to conduct and require more time. "I think that over the next few years we should be able to develop these combination vaccines that would really provide very comprehensive public health protection."
